TrialGynecologic oncology2017

A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study.

Carolyn K McCourt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.